scholarly journals Mycoplasma genitalium in Singapore is associated with Chlamydia trachomatis infection and displays high macrolide and Fluoroquinolone resistance rates

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Tim Hart ◽  
Wen Ying Tang ◽  
Siti Aminah bte Mansoor ◽  
Martin T. W. Chio ◽  
Timothy Barkham
Keyword(s):  
Chlamydia Trachomatis ◽  
Mycoplasma Genitalium ◽  
Fluoroquinolone Resistance ◽  
Chlamydia Trachomatis Infection ◽  
Resistance Rates

scholarly journals Mycoplasma genitalium in Singapore is Associated with Chlamydia trachomatis Infection and Displays High Macrolide and Fluoroquinolone Resistance Rates

2019 ◽  
Author(s):  
Tim Hart ◽  
Wen Ying Tang ◽  
Siti Aminah Mansoor ◽  
Martin Tze-Wei Chio ◽  
Timothy Sebastian Barkham
Keyword(s):  
Cost Effective ◽  
Mycoplasma Genitalium ◽  
Fluoroquinolone Resistance ◽  
Health Clinic ◽  
Resistance Mutations ◽  
Transmitted Infection ◽  
Chlamydia Trachomatis Infection ◽  
Sexually Transmitted ◽  
Recommended Treatment ◽  
Resistance Rates

Abstract Mycoplasma gentialium is considered to be an emerging sexually transmitted infection, with increasing rates of resistance to fluroquinolones and macrolides, the most recommended treatment. Despite this, M. genitalium is not part of routine screening for Sexually Transmitted Infections (STIs) in many countries. We report the results of a study into M. genitalium prevalence at the national sexual health clinic in Singapore. M. genitalium was heavily associated with C. trachomatis (CT) infection (8.1% of cases), but not independently with N. gonorrhoea (NG) infection and present in only of 2.4% in CT negative cases. Furthermore, we found high rates of resistance mutations to both macrolides (25%) and fluoroquinolones (37.5%) with the majority of resistant isolates dual-resistant. Resistance mutations were only found in isolates from patients with CT co-infection. Screening CT positive patients for M. genitalium infection, followed by appropriate extended treatment, could be a cost-effective strategy to reduce the incidence of M. genitalium and reduce levels of antibiotic resistance.

Macrolide and fluoroquinolone resistance of Mycoplasma genitalium in southern Spain, 2018–2019

2020 ◽  
pp. sextrans-2019-054386
Author(s):  
Adolfo de Salazar ◽  
Antonio Barrientos-Durán ◽  
Beatriz Espadafor ◽  
Ana Fuentes-López ◽  
Natalia Chueca ◽  
...  
Keyword(s):  
General Population ◽  
Mycoplasma Genitalium ◽  
Southern Spain ◽  
Fluoroquinolone Resistance ◽  
23S Rrna ◽  
Heterosexual Men ◽  
Second Line ◽  
First Line ◽  
Sex With Men ◽  
Resistance Rates

ObjectivesIn recent years, resistance in Mycoplasma genitalium (MG) to first-line (azithromycin) and second-line (moxifloxacin) treatment has been increasingly reported worldwide, however, no data regarding the south of Spain are available.MethodsTo determine resistance rates, MG-positive samples collected from June 2018 to June 2019 were analysed by sequencing the 23S rRNA and parC genes.ResultsA total of 77 patients (24 men having sex with men (MSM), 30 heterosexual men and 23 women) were included. Resistance-associated mutations against macrolide and fluoroquinolones were found in 36.4% (95% CI 25.7% to 48.1%) and 9.1% (95% CI 3.7% to 17.8%) of the patients, respectively. Being MSM and having had another STI in the last year were significantly associated with macrolide-resistant MG infection, while no associations were found with resistance to fluoroquinolones.ConclusionsTesting for resistance to first-line and second-line drugs against MG should be recommended for the general population and mandatory for the MSM population. We suggest that empiric azithromycin use for STI management should be avoided.

Mycoplasma genitalium Antibiotic Resistance–Mediating Mutations in Canadian Women With or Without Chlamydia Trachomatis Infection

2017 ◽  
Vol 44 (7) ◽  
pp. 433-435 ◽  
Author(s):  
Max A. Chernesky ◽  
Dan Jang ◽  
Irene Martin ◽  
Linda M.N. Hoang ◽  
Prenilla Naidu ◽  
...  
Keyword(s):  
Antibiotic Resistance ◽  
Chlamydia Trachomatis ◽  
Mycoplasma Genitalium ◽  
Chlamydia Trachomatis Infection

scholarly journals Mycoplasma genitalium Coinfection in Women With Chlamydia trachomatis Infection

2019 ◽  
Vol 46 (10) ◽  
pp. e101-e104 ◽  
Author(s):  
Sally A. Harrison ◽  
Kristin M. Olson ◽  
Amy E. Ratliff ◽  
Li Xiao ◽  
Barbara Van Der Pol ◽  
...  
Keyword(s):  
Chlamydia Trachomatis ◽  
Mycoplasma Genitalium ◽  
Chlamydia Trachomatis Infection

scholarly journals Prevalence of urogenital, anal, and pharyngeal infections with Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium: a cross-sectional study in Reunion island

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
A. Calas ◽  
N. Zemali ◽  
G. Camuset ◽  
J. Jaubert ◽  
R. Manaquin ◽  
...  
Keyword(s):  
Chlamydia Trachomatis ◽  
Neisseria Gonorrhoeae ◽  
Mycoplasma Genitalium ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Transmitted Infection ◽  
Cross Sectional ◽  
Sexually Transmitted ◽  
Urogenital Infection ◽  
High Prevalence

Abstract Background Recommendations for sexually transmitted infection (STI) screening vary significantly across countries. This study evaluated the prevalence of urogenital and extragenital infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) in patients visiting a French STI clinic in the Indian Ocean region to determine whether current STI screening practices should be updated. Methods This cross-sectional study examined all patients who visited the STI clinic between 2014 and 2015. Triplex polymerase chain reaction screening for CT, NG, and MG was performed on urine, vaginal, pharyngeal, and anal specimens (FTD Urethritis Basic Kit, Fast Track Diagnostics, Luxembourg). Results Of the 851 patients enrolled in the study, 367 were women (367/851, 43.2%) and 484 were men (484/851, 56.0%). Overall, 826 urogenital specimens (826/851, 97.1%), 606 pharyngeal specimens (606/851, 71.2%), and 127 anal specimens (127/851, 14.9%) were taken from enrolled patients. The prevalence of urogenital CT and MG was high in women ≤25 years (19/186, 10.21%; 5/186, 2.69%) and in men who have sex with women ≤30 years (16/212, 7.54%; 5/212, 2.36%). Among patients with urogenital CT infection, 13.7% (7/51) had urethritis. All patients with urogenital MG infection were asymptomatic. Men who have sex with men had a high prevalence of pharyngeal CT (2/45, 4.44%) and NG (3/44, 6.81%) and a high prevalence of anal CT (2/27, 7.41%), NG (2/27, 7.40%), and MG (1/27, 3.70%). After excluding patients with concomitant urogenital infection, extragenital infections with at least 1 of the 3 pathogens were found in 20 swabs (20/91, 21.9%) taken from 16 patients (16/81, 19.7%), all of them asymptomatic. Conclusions Routine multisite screening for CT, NG, and MG should be performed to mitigate the transmission of STIs in high-risk sexually active populations.

Resistance-guided treatment of Mycoplasma genitalium infection at a UK sexual health centre

2021 ◽  
pp. 095646242098776
Author(s):  
Ruairi JH Conway ◽  
Seamus Cook ◽  
Cassandra Malone ◽  
Simon Bone ◽  
Mohammed Osman Hassan-Ibrahim ◽  
...  
Keyword(s):  
Single Dose ◽  
Confidence Interval ◽  
Sexual Health ◽  
Treatment Failure ◽  
Inflammatory Disease ◽  
Health Centre ◽  
Mycoplasma Genitalium ◽  
Macrolide Resistance ◽  
Fluoroquinolone Resistance ◽  
Treatment Failure Rate

We evaluated the ResistancePlus® MG assay in providing macrolide resistance-guided treatment (RGT) for Mycoplasma genitalium infection at a UK sexual health centre. M. genitalium–positive samples from men with urethritis and women with pelvic inflammatory disease (PID) were tested for macrolide resistance–mediating mutations (MRMMs). MRMM-positive infections were given moxifloxacin 400 mg; otherwise 2 g azithromycin (1 g single dose and then 500 mg OD) was given. Among 57  M. genitalium–positive patients (32 men and 25 women), MRMMs were detected in 41/57 (72% [95% confidence interval (95% CI) 58–83%). Thirty-two of 43 patients given RGT attended for test of cure. Treatment failure rate was significantly lower at 1/32 (3%) than 10/37 (27%) before RGT ( n = 37 [men = 23 and women = 17]; p = 0.008). Treatment failure was lower in male urethritis (0/15 vs. 7/21 p = 0.027) but not in female PID. There was a trend of a shorter time to negative test of cure (TOC) in male urethritis (55.1 [95% 43.7–66.4] vs. 85.1 [95% CI CI 64.1–106.0] days, p = 0.077) but not in female PID. Macrolide resistance is higher than previous UK reports and higher than expected. RGT reduces overall treatment failure and is particularly beneficial in M. genitalium urethritis. Fluoroquinolone resistance will continue to rise with increasing fluoroquinolone use, and RGT is critical to direct appropriate azithromycin use and prevent overuse of moxifloxacin.

Sign in / Sign up

Export Citation Format

Share Document